Author Archives | DavidRobinson
DavidRobinson - who has written 16 posts on FavStocks.
Dave Robinson mainly focuses his research on various aspects of corporate finance and financial reporting. He tracks how stock prices respond to new earning releases, for companies in a wide variety of sectors.
Dave also enjoys looking for companies in currently unpopular industries, experiencing a short term setbacks in earnings, or spinoffs and asset sales, into newly created companies, and he aims to find these before they are discovered by the majority of other investors
He received his MBA in Accounting and Finance from University of Houston.
Acorda Trading Halted (NASDAQ:ACOR)
It was not a good start for Acorda Therapeutics on Wednesday morning when NASDAQ decided to halt the trading of Acorda Therapeutics shares until the experts have voted on Acorda’s new MS drug.
Continue reading...Vanda Inks Novartis Deal (NASDAQ:VNDA)
14 October 2009
Comments Off
On Monday morning, shares of Vanda Pharmaceuticals went up sharply after the announcement that they have inked a new licensing deal with Novartis that would earn them around US$ 465 million, of which US$ 200 million will be paid as upfront fees by Novartis.
Continue reading...Repros Therapeutics Offering (NASDAQ:RPRX)
9 October 2009
Comments Off
Just a day after the success of its male hormonal treatment, Androxal, Repros Therapeutics Inc announced that they are willing to sell 3.5 million shares of stock to institutional investors at a discounted price of $1.27 per share.
Continue reading...ADVENTRX Announces Financing (AMEX:ANX)
7 October 2009
Comments Off
ADVENTRX Pharmaceuticals have announced that they have received license to purchase shares of its Series D convertible preferred stock pursuant to registered direct offering to institutional investors that will represent gross proceeds to ADVENTRX of US$ 11.3 million. ADVENTRX has planned to use all the financing received to fund the operations during the period when [...]
Continue reading...Allergan sues FDA (NYSE:AGN)
5 October 2009
Comments Off
One of the well known makers of the Botox wrinkle treatment, Allergan Inc, has gathered its courage and challenged the government’s ban on off-label drug marketing to doctors. The company challenges this idea by the FDA saying that it violates the company’s right to freedom of speech. The company has clearly stated in its lawsuit [...]
Continue reading...Vertex strapped for cash (NASDAQ:VRTX)
1 October 2009
Comments Off
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) sold the rights to its key milestone payments for their hepatitis C drug in development telaprevir, worth up to $95 million. VRTX also raised $155 million by issuing new issuing notes due in 10/31/2012. It sounds like the company needed money fast, and thats exactly the news VRTX came out with next to [...]
Continue reading...
16 October 2009
Comments Off